Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
Authors' conclusion
Perceived hunger and tendency to overeat (disinhibition) were reduced with higher doses of retatrutide, compared with placebo. Greater weight reduction was associated with decreased perceived hunger and disinhibition and increased dietary restraint.
Study context
- Population
- Adults with T2D
- Participants
- 275 adults
- Comparison
- Retatrutide vs placebo or dulaglutide
- Primary endpoint
- Changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores
- Follow-up
- 24 and 36 weeks
Methodological detailspre-specified exploratory analyses, post-hoc correlations
- Pre-specified exploratory analyses
- Post-hoc correlations
Primary result
As reported in the abstract
Weeks 24 and 36
- Retatrutide ≥4 mg vs placebo: greater reductions in overall appetite, hunger and prospective food consumption at Week 24 (all p <0.05)
- Differences vs dulaglutide less consistent
- Retatrutide 8 and 12 mg vs placebo: greater improvements in Eating Inventory (EI) Perceived Hunger and Disinhibition at Weeks 24 and 36
- Dietary Restraint increased vs placebo only with retatrutide 12 mg at Week 36 (all p <0.05)
Further findings
Correlation of changes in EI scores with body weight reduction (post-hoc) · Week 36
- Reduction in Perceived Hunger, r
- 0.28
- Reduction in Disinhibition, r
- 0.36
- Increase in Dietary Restraint, r
- 0.31
- Significantly correlated
Original publication
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. Published 8 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →